Avadomide

Avadomide is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide exhibits potent antitumor and immunomodulatory activities[1][2][3].

Product Specifications

CAS Number

[1015474-32-4]

Product Name Alternative

CC 122

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; E1/E2/E3 Enzyme; Molecular Glues; NF-κB

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; NF-κB; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/CC122.html

Purity

99.56

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=C(C(N1C(C)=NC2=C(C(N)=CC=C2)C1=O)CC3)NC3=O

Molecular Formula

C14H14N4O3

Molecular Weight

286.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Hagner, P.R.et al.CC-122, a pleiotropic pathway modifier, mimics an IFN response and has antitumor activity in DLBCL.Blood.Aug 6;126 (6) :779-89.|[2]Rasco DW, et al. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin Cancer Res. 2019 Jan 1;25 (1) :90-98.|[3]Nishi H, et al., Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2023 Oct;92 (4) :303-314.